In this issue of Blood, Bonzheim et al have reported the diagnostic value of the assessment of MYD88 L265P (MYD88) mutations in vitreoretinal lymphoma.1 In general terms, the diagnosis of lymphoma classically requires standard histopathologic, immunophenotypical, genetic, and molecular criteria that are combined to a variable extent to define individual clinicopathologic entities recognized by World Health Organization classification. These gold standard requisites may not be fulfilled in some rare particular instances, resulting in diagnostic difficulties. One challenging example of this latter occurrence is represented by vitreoretinal diffuse large B-cell lymphoma. The identification of vitreoretinal diffuse large B-cell lymphoma is crucial for 2 main reasons. First, this type of lymphoma is particularly aggressive and must be distinguished from lowgrade marginal-zone B-cell lymphomas of the choroid, and second, vitreoretinal diffuse large B-cell lymphoma could represent the intraocular dissemination of a concomitant diffuse large B-cell lymphoma of the central nervous system (PCNSL). PCNSL is another and more frequent type of aggressive B-cell lymphoma that needs to be promptly recognized and treated.
ASJC Scopus subject areas
- Cell Biology